CLVS.Q Aktienübersicht
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 0/6 |
| Dividenden | 0/6 |
Clovis Oncology, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$0.015 |
| 52-Wochen-Hoch | US$2.87 |
| 52-Wochen-Tief | US$0.01 |
| Beta | 0.66 |
| 11 Monat Veränderung | -40.00% |
| 3 Monate Veränderung | -28.57% |
| 1 Jahr Veränderung | -99.39% |
| 33 Jahre Veränderung | -99.77% |
| 5 Jahre Veränderung | -99.97% |
| Veränderung seit IPO | -99.88% |
Aktuelle Nachrichten und Updates
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Aktionärsrenditen
| CLVS.Q | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 18.1% | -2.8% | 0.7% |
| 1Y | -99.4% | 19.3% | 32.3% |
Rendite im Vergleich zur Industrie: CLVS.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Rendite vs. Markt: CLVS.Q underperformed the US Market which returned 12.6% over the past year.
Preisvolatilität
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: CLVS.Q's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: CLVS.Q's weekly volatility has increased from 39% to 61% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc.'s Grundlagenzusammenfassung
| CLVS.Q grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.18m |
| Gewinn(TTM) | -US$251.91m |
| Umsatz(TTM) | US$133.02m |
0.0x
Kurs-Umsatz-Verhältnis0.0x
Kurs-Gewinn-VerhältnisIst CLVS.Q zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CLVS.Q Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$133.02m |
| Kosten der Einnahmen | US$31.59m |
| Bruttogewinn | US$101.43m |
| Sonstige Ausgaben | US$353.33m |
| Umsatz | -US$251.91m |
Zuletzt gemeldete Gewinne
Sep 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.73 |
| Bruttomarge | 76.25% |
| Nettogewinnspanne | -189.37% |
| Schulden/Eigenkapital-Verhältnis | -158.0% |
Wie hat sich CLVS.Q auf lange Sicht entwickelt?
Historische Performance und Vergleiche